MicroPort CardioFlow Medtech Corporation announced that the third-generation transcatheter aortic heart valve implantation product independently developed by the Group ("Third-Generation TAVI Product") which is equipped with an upgraded retrievable steerable delivery system was successfully applied by the heart teams of Fuwai Hospital of the Chinese Academy of Medical Sciences and Shanxi Provincial Hospital of Cardiovascular Diseases to treat two patients with severe aortic stenosis. The patients are now recovering well with significant relief of related symptoms. The successful first-in-man applications of Third-Generation TAVI Product marked its entry into the clinical application phase and further enriched TAVI product offering to increase competitiveness. Originated from the Group's deep understanding of clinical needs and pain points, self-developed Third-Generation TAVI Product is an iteration of VitaFlow Liberty®, second-generation TAVI product which is now widely used in TAVI procedures.

The delivery system of this product is upgraded with a highly innovative steerable function, which is designed to help cross the aortic arch and the native valve, facilitate the delivery process to achieve less tissue damage, enhance valve coaxiality during pre-positioning and release, make it easier to anchor in the appropriate position, further reduce the maneuver difficulty and increase positioning accuracy, thus improving the procedure success rate and enhancing the therapeutic effects. The unique spatial curvature is more in line with the human heart structure and is suitable for a variety of challenging anatomies. Meanwhile, the limit switch on the handle of the delivery system helps physicians to reduce the rate of intraoperative mishandling and further optimizes the procedure process.

The first two successful clinical applications of the Third-Generation TAVI Product is another important milestone of the Group's comprehensive deployment in the field of structural heart disease, and a manifestation of solid technical reserves and innovative research & development capabilities in the field of structural heart diseases. The product impresses physicians with its excellent ease-of-use, more accurate positioning and improved procedure efficiency. look forward to the launch of the Third-Generation TAVI Product as soon as possible to treat more patients with aortic valve disease.